Beginning to understand high-density lipoproteins

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 4, 2014, Pages 913-947

  Santos Gallego, Carlos G ^a   Badimon, Juan J ^a   Rosenson, Robert S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; Cholesteryl ester transfer protein inhibitor; Fibrates; High density lipoprotein; High density lipoprotein particles; Niacin; Reverse cholesterol transport

Indexed keywords

ANACETRAPIB; ATORVASTATIN; BEZAFIBRATE; CARDIOVASCULAR AGENT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DALCETRAPIB; EVACETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; NICOTINIC ACID; PLACEBO; PROTEOME; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RESVERLOGIX; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; APOLIPOPROTEIN A1; BIOLOGICAL MARKER;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROTECTION; CHOLESTEROL TRANSPORT; DIET; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HEART PROTECTION; HUMAN; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; REPERFUSION INJURY; RISK REDUCTION; SMOKING CESSATION; THROMBOSIS; VASODILATATION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; CHEMISTRY; METABOLISM; PHYSIOLOGY;

ANIMALIA;

APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL; METABOLIC NETWORKS AND PATHWAYS;

EID: 84921685955     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.08.001     Document Type: Review

References (190)

1. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357(13):1301-10.
2. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;85(4):1234-41.
3. Badimon JJ, Badimon L, Galvez A, et al. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989;60(3):455-61.
4. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353(6341):265-7.
5. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-300.
6. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297(15):1675-82.
7. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380(9841):572-80.
8. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376(9738):333-9.
9. Ray K, Wainwright NW, Visser L, et al. Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 2012;98(10):780-5.
10. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
11. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24):2255-67.
12. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371(3):203-12.
13. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089-99.
14. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74.
15. Rosenson RS, Brewer HB Jr, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013;128(11):1256-67.
16. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29(6):870-6.
17. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013;7(5):484-525.
18. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115(4):501-8.
19. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113(4): 569-81.
20. Poti F, Simoni M, Nofer JR. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc Res 2014;103: 395-404.
21. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13(4):423-33.
22. Wagner J, Riwanto M, Besler C, et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol 2013;33(6):1392-400.
23. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57(3):392-410.
24. Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol 2008;76(4):443-52.
25. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125(15):1905-19.
26. Santos-Gallego CG, Torres F, Badimon JJ. The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidol 2011;6(2):181-208.
27. Santos-Gallego CG, Giannarelli C, Badimon JJ. Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. Curr Atheroscler Rep 2011;13(3):266-76.
28. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 2011;364(2): 127-35.
29. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33(7):1696-705.
30. Doonan RJ, Hafiane A, Lai C, et al. Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology. Arterioscler Thromb Vasc Biol 2014; 34(4):921-6.
31. Camont L, Lhomme M, Rached F, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013;33(12):2715-23.
32. Feig JE, Hewing B, Smith JD, et al. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 2014;114(1): 205-13.
33. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111(12): 1543-50.
34. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15(11):1987-94.
35. Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidasemodified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2014;34(4):779-89.
36. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28(11):2071-7.
37. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121(10):4138-49.
38. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012;11(2):195-206.
39. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7(7): 853-7.
40. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263(3):256-73.
41. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006;98(1):63-72.
42. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105(12): 1399-402.
43. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107(23):2944-8.
44. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121(7):2693-708.
45. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun 2000;272(3):872-6.
46. Suc I, Escargueil-Blanc I, TrolyM, et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997;17(10): 2158-66.
47. Yvan-Charvet L, Pagler TA, Seimon TA, et al. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res 2010;106(12):1861-9.
48. Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007;27(8):1843-9.
49. Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005;112(6):893-9.
50. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999;19(2):378-83.
51. Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999;103(2):219-27.
52. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009;120(21):2095-104.
53. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98(11):1352-64.
54. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007;13(3):340-7.
55. Vergeer M, Brunham LR, Koetsveld J, et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010;33(4): 869-74.
56. Drew BG, Rye KA, Duffy SJ, et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012;8(4):237-45.
57. Drew BG, Duffy SJ, FormosaMF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009;119(15): 2103-11.
58. Han R, Lai R, Ding Q, et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007;50(9):1960-8.
59. Drew BG, Carey AL, Natoli AK, et al. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. J Lipid Res 2011;52(3):572-81.
60. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114(13):1403-9.
61. Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003;92(3):330-7.
62. Rossoni G, Gomaraschi M, Berti F, et al. Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. J Pharmacol Exp Ther 2004;308(1):79-84.
63. Marchesi M, Booth EA, Rossoni G, et al. Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis 2008;197(2):572-8.
64. Sattler KJ, Herrmann J, Yun S, et al. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J 2009;30(15):1894-902.
65. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96(6):2758-67.
66. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103(18):2283-8.
67. Morgantini C, Natali A, Boldrini B, et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 2011;60(10):2617-23.
68. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114(4):529-41.
69. Huang Y, Didonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203.
70. Hoang A, Murphy AJ, Coughlan MT, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007;50(8):1770-9.
71. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108(22):2751-6.
72. Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial antiand proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013;127(8):891-904.
73. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121(1):110-22.
74. Choudhury RP, Leyva F. C-Reactive protein, serum amyloid A protein, and coronary events. Circulation 1999;100(15):e65-6.
75. Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005;48(3):529-38.
76. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22(9):1631-41.
77. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012;23(5):934-47.
78. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007;72(9): 1149-56.
79. de Souza JA, Vindis C, Hansel B, et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective antiapoptotic activity. Atherosclerosis 2008;197(1):84-94.
80. Zerrad-Saadi A, Therond P, Chantepie S, et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009;29(12):2169-75.
81. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002;90(8A):22i-9i.
82. Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010;122(5):470-7.
83. Acharjee S, Boden WE, Hartigan PM, et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol 2013;62(20):1826-33.
84. Kuller LH, Grandits G, Cohen JD, et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007;195(1):122-8.
85. Mackey RH, Greenland P, Goff DC Jr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60(6): 508-16.
86. Akinkuolie AO, Paynter NP, Padmanabhan L, et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes 2014;7(1):55-63.
87. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113(12):1556-63.
88. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013; 128(11):1189-97.
89. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010;30(7):1430-8.
90. Airan-Javia SL, Wolf RL, Wolfe ML, et al. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy. Am Heart J 2009;157(4):687.e1-8.
91. Khera AV, Patel PJ, Reilly MP, et al. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 2013;62(20):1909-10.
92. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341(6):410-8.
93. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347(19):1483-92.
94. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167(10):999-1008.
95. Kelley GA, Kelley KS. Aerobic exercise and HDL2-C: a meta-analysis of randomized controlled trials. Atherosclerosis 2006;184(1):207-15.
96. Roberts CK, Ng C, Hama S, et al. Effect of a short-termdiet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol (1985) 2006;101(6):1727-32.
97. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007;56(11):2655-67.
98. Wood PD, Stefanick ML, Williams PT, et al. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991;325(7):461-6.
99. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56(2):320-8.
100. Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss. Eur Heart J Suppl 2005;7(Suppl L):L21-6.
101. Schwartz RS, Brunzell JD. Increase of adipose tissue lipoprotein lipase activity with weight loss. J Clin Invest 1981;67(5):1425-30.
102. Weisweiler P. Plasma lipoproteins and lipase and lecithin:cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 1987;65(5):969-73.
103. Aron-Wisnewsky J, Julia Z, Poitou C, et al. Effect of bariatric surgery-induced weight loss on SR-BI-, ABCG1-, and ABCA1-mediated cellular cholesterol efflux in obese women. J Clin Endocrinol Metab 2011;96(4):1151-9.
104. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329(25):1829-34.
105. Valmadrid CT, Klein R, Moss SE, et al. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999;282(3):239-46.
106. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348(2):109-18.
107. Costanzo S, Di Castelnuovo A, Donati MB, et al. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2010;55(13):1339-47.
108. Mukamal KJ, Chen CM, Rao SR, et al. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol 2010;55(13): 1328-35.
109. Klatsky AL, Friedman GD, Siegelaub AB. Alcohol and mortality. A ten-year Kaiser-Permanente experience. Ann Intern Med 1981;95(2):139-45.
110. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298(6676): 784-8.
111. Richard F, Marecaux N, Dallongeville J, et al. Effect of smoking cessation on lipoprotein A-I and lipoprotein A-I: A-II levels. Metabolism 1997;46(6):711-5.
112. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003;37(4): 283-90.
113. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292(12):1440-6.
114. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterraneanstyle diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006;145(1):1-11.
115. Damasceno NR, Sala-Vila A, Cofan M, et al. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis 2013;230(2):347-53.
116. Sala-Vila A, Romero-Mamani ES, Gilabert R, et al. Changes in ultrasoundassessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial. Arterioscler Thromb Vasc Biol 2014; 34(2):439-45.
117. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368(14):1279-90.
118. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006;48(4):715-20.
119. Lankinen M, Kolehmainen M, Jaaskelainen T, et al. Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activities: a randomized trial (Sysdimet). PLoS One 2014;9(2):e90352.
120. Frost G, Leeds AA, Dore CJ, et al. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 1999;353(9158):1045-8.
121. Ford ES, Liu S. Glycemic index and serum high-density lipoprotein cholesterol concentration among us adults. Arch Intern Med 2001;161(4):572-6.
122. Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010;51(6):1546-53.
123. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009;32(6):1087-91.
124. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999;144(1):177-84.
125. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31(2):149-64.
126. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163(2):287-96.
127. Niesor EJ, Schwartz GG, Suchankova G, et al. Statin decrease in transporter ABC A1 expression via miR33 induction may counteract cholesterol efflux by high-density lipoproteins raised with the cholesteryl ester transfer protein modulator dalcetrapib. American College of Cardiology 2013 Scientific Sessions. San Francisco, California. March 9-11, 2013.
128. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-93.
129. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317(20):1237-45.
130. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85(1):37-45.
131. Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102(1):21-7.
132. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32(3):493-8.
133. Davidson MH, Rosenson RS, Maki KC, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol 2014;34(6):1298-306.
134. Song WL, Stubbe J, Ricciotti E, et al. Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans. J Clin Invest 2012;122(4):1459-68.
135. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323(18):1234-8.
136. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338(2):86-93.
137. Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008;29(22):2792-9.
138. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120(24):2414-20.
139. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121(3):366-74.
140. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350(15):1505-15.
141. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22.
142. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356(13):1304-16.
143. Bots ML, Visseren FL, EvansGW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370(9582):153-60.
144. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356(16): 1620-30.
145. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27(5):1132-8.
146. Bellanger N, Julia Z, Villard EF, et al. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012; 221(1):160-8.
147. Simic B, Hermann M, Shaw SG, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2012;33(13):1615-24.
148. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009;150(5):2211-9.
149. Sofat R, Hingorani AD, Smeeth L, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121(1):52-62.
150. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105(18):2159-65.
151. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378(9802):1547-59.
152. Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33(7):857-65.
153. Ray KK, Ditmarsch M, Kallend D, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014; 35(27):1792-800.
154. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15.
155. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010;55(23):2580-9.
156. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011; 57(9):1111-9.
157. Puri R, Kataoka Y, Wolski K, et al. Effects of an apolipoprotein A-1 inducer on progression of coronary atherosclerosis and cardiovascular events in patients with elevated inflammatory markers. American College of Cardiology 2014 Scientific Sessions. Washington, DC. March 29-31, 2014.
158. Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66(5):892-900.
159. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001;103(15):1949-54.
160. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998;97(8):780-5.
161. Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008;51(11):1104-9.
162. Kaul S, Rukshin V, Santos R, et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003;107(20):2551-4.
163. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 2004;44(6):1311-9.
164. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006;47(5):992-7.
165. Eriksson M, Carlson LA, Miettinen TA, et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999;100(6):594-8.
166. Gille A, D'Andrea D, Easton R, et al. CSL112, a novel formulation of human apolipoprotein A-I, dramatically increases cholesterol efflux capacity in patients with stable atherothrombotic disease: a multicenter, randomized, double-blind, placebo-controlled, ascending-dose study. Circulation 2013;128:A15780.
167. Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014. [Epub ahead of print].
168. Hovingh GK, Stroes ES, Gaudet D. Effects of CER-001 on carotid atherosclerosis by 3TMRI in homozygous familial hypercholesterolaemia (HOFH): the modifying orphan disease evaluation (MODE) study. European Atherosclerosis Society Scientific Meeting 2014. Madrid, Spain, June 2, 2014.
169. Kootte RS, Smits LP, van der Valk FM. Recombinant human apolipoprotein-A-I prebeta-HDL (CER-001) promotes reverse cholesterol transport and reduces carotid wall thickness in patients with genetically determined low HDL. European Atherosclerosis Society Scientific Meeting 2014. Madrid, Spain, June 2, 2014.
170. Sacks FM, Rudel LL, Conner A, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009;50(5):894-907.
171. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebocontrolled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55(24):2727-35.
172. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001;42(4):545-52.
173. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011;52(2):361-73.
174. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105(3): 290-2.
175. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008;49(6):1344-52.
176. Chattopadhyay A, Navab M, Hough G, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res 2013;54(4):995-1010.
177. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010;30(2):246-52.
178. Iwata A, Miura S, Zhang B, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011;218(2):300-7.
179. Miller NE, Thelle DS, Forde OH, et al. The Tromso Heart Study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1(8019):965-8.
180. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256(20): 2835-8.
181. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248(12):1465-77.
182. Lipid Research Clinics Program. JAMA 1984;252(18):2545-8.
183. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11-20.
184. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17(1):107-13.
185. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104(10):1108-13.
186. Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002;22(7):1155-61.
187. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347(9005):849-53.
188. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96(7):2137-43.
189. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-10.
190. Sibley CT, Vavere AL, Gottlieb I. MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart 2013;99(22):1675-80.